NeuraLace Medical Expands Global Patent Portfolio as Clinical Strategy Moves Forward

News provided by

Neuralace Medical, Inc.

19 Apr, 2022, 09:00 ET

New Patents Protect innovative Axon™ Therapy, a Non-Invasive and Non-Pharmacological Solution for Treating Neuropathic Pain, as NeuraLace's Clinical Strategy Advances Focusing on Neuropathic Pain Related to Surgery, Trauma and Diabetic Neuropathy

SAN DIEGO , April 19, 2022 /PRNewswire/ -- NeuraLace Medical, Inc., a commercial-stage medical technology company focusing on innovative solutions for neuropathic pain care, announces the expansion of its global patent portfolio with the issuance of two new patents: US Patent No. 11,305,130 for "Devices, Systems, and Methods For Non-Invasive Chronic Pain Therapy" (issued April 19, 2022) and US Patent No. 11,273,317 for "Portable Transcutaneous Magnetic Stimulator and Systems and Methods of Use Thereof" (issued March 15, 2022).

Continue Reading

The new patents include system and method claims for treating peripheral nerve pain using low-frequency transcutaneous magnetic stimulation, including advanced applications in wearable pain therapy technology.  The patents, which last until 2039 and 2033, respectively, are part of a global patent portfolio protecting the core Axon™ Therapy and advanced applications such as robotics for applying Axon Therapy, including U.S. Patent No. 10,369,373 issued on August 6, 2019 and U.S. Patent No. 11,058,887 issued on July 13, 2021.

"We are pleased to strengthen our intellectual property protection with the addition of these new US patents," stated Keith Warner, Chief Executive Officer of NeuraLace Medical.  "Along with our robust international IP portfolio, these patents bolster and expand the protection of our core Axon technology, highlighted by the use of transcutaneous magnetic stimulation as opposed to invasive and/or pharmacological solutions.  The company's clinical results thus far have been impressive, and we look forward to this momentum carrying forward to the completion and publication of our formal clinical studies."

The company is in the process of expanding sites of its ongoing randomized clinical trial focusing on application of Axon therapy to neuropathic pain broadly, while also initiating a large study focusing on peripheral diabetic neuropathy, recognizing that for millions of patients the drugs used in first line therapy become ineffective or are not well tolerated, and other modalities of treatment are needed. 

About NeuraLace Medical
Privately held NeuraLace Medical, Inc., headquartered in San Diego, Calif., is committed to leading the charge in non-invasive chronic pain management and sustainable relief.  Our mission to end chronic pain inspired us to develop Axon Therapy, with the goal of being the first non-invasive, non-addictive way to effectively treat chronic nerve pain.  

With its unique product portfolio, protected by property patents and patent applications, NeuraLace Medical is well positioned to establish a leadership position in the medical device market.   For more information, please visit www.neuralacemedical.com.

For more information, please contact: 
Keith Warner
Chief Executive Office
[email protected] 

SOURCE Neuralace Medical, Inc.

Also from this source

Neuralace Medical Announces Clinical Milestones Including Presentation of the Safety and Efficacy of Axon Therapy (SEAT) Study at the American Society of Pain and Neuroscience Conference (ASPN), While Completing Enrollment in the Axon Therapy Painful Diabetic Neuropathy Study (AT-PDN) and Launching a Pilot Study Focused on the Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN)

Dr. Peter Staats, Chief Medical Officer at National Spine and Pain, Joins the Neuralace Medical Advisory Board as the Company Continues its Successful Seed Round Fundraising, Building Off the First Close of $3.1M While Targeting a Total Capital Raise of $5M-$7M

Explore

More news releases in similar topics

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.